FDA Output
FDA Output June 2024
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in June 2024. Updated June 11, 2024.
Welcome to MyStrategist, the digital home for Market Pathways.
Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
FDA Output
FDA Output June 2024
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in June 2024. Updated June 11, 2024.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways' Picks
China Reforms, Digital Health Picks, Cures 2.0 Reboot, and More
In this week’s Pathways Picks: China approves new clinical trial oversight rules and eyes health system reforms; US industry groups will get their day in court against the Library of Congress; digital therapeutics accreditation planned; study shows women are still under-enrolled in device trials; lawmakers seek input for a new Cures 2.0 innovation bill; and more on digital health, health technology assessments, and adverse event reporting.